Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Xuewu Liu, a Chinese inventor who has no medical training or credentials of any kind, is charging cancer patients $20,000 for ...

Lepore starts Aug. 18 at Air Products, which has 23,000 employees spread across 50 countries and ranks 347th in the Fortune ...

A Chinese man with no medical training is injecting cancer patients with a toxic bleach solution; a full course of treatment ...

Nationwide employment law firm Jackson Lewis PC has added Kaha Kvachatadze as a principal in its White Plains office. He ...

Depo-Provera is a birth control shot that is injected every three months and features a type of progestin hormone called ...

Severance plans subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”) must satisfy certain compliance requirements, ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

The appointment of a seasoned pharmaceutical executive, George Tidmarsh, to run the FDA’s drug center underscores the ...

The Trump administration is asking the Supreme Court to allow it to cut hundreds of millions of dollars’ worth of research ...